Trial of potential Ebola treatments begins in DR Congo

A clinical trial for two potential Ebola treatments, MBP134 and remdesivir, has begun in the Democratic Republic of Congo (DRC) to address the Bundibugyo strain of the virus. The trial is led by the World Health Organization (WHO) and local health authorities. The Bundibugyo strain is less common than the Zaire strain but has caused previous outbreaks with significant mortality. The trial aims to evaluate the safety and efficacy of these treatments in a real-world outbreak setting. This initiative follows the success of similar trials during the 2018-2020 Ebola outbreak in the DRC, which helped reduce fatality rates. The current outbreak, declared in April 2024, has already resulted in dozens of cases and deaths in the Equateur province. Health officials emphasize the urgency of finding effective treatments for this strain to prevent wider spread.

Global Impact

The trial has significant public health implications for sub-Saharan Africa, where Ebola outbreaks are recurrent. A successful treatment for the Bundibugyo strain would fill a critical gap, as existing vaccines and therapies are primarily for the Zaire strain.